Patent litigation: a global perspective
Patent protection is a global affair, so if you find yourself embroiled in litigation, it helps to know what benefits and challenges different jurisdictions can offer.
Mylan fails to void MSD diabetes treatment patent at PTAB
MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.
Brazil rules 10-year patent term ‘unconstitutional’
Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.
WIPO unveils course on genetic resources in the life sciences
The World Intellectual Property Office has launched a course on IP and genetic resources in the life sciences.
Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit
Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals.
Conformis launches implant lawsuit against J&J subsidiary
US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.
Novartis withdraws bid to block US Regeneron imports
Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Fed Circ. agrees Bio-Rad infringed 10x patents
The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
GSK claims Amgen v Sanofi decision “threatens” innovation
GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Dr Reddy’s hits Amarin with antitrust suit over Vascepa
Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.
